Dataset Information


Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.

ABSTRACT: T-cell acute lymphoblastic leukemia (T-ALL), a T-cell malignant disease that mainly affects children, is still a medical challenge, especially for refractory patients for whom therapeutic options are scarce. Recent advances in immunotherapy for B-cell malignancies based on increasingly efficacious monoclonal antibodies (mAbs) and chimeric antigen receptors (CARs) have been encouraging for non-responding or relapsing patients suffering from other aggressive cancers like T-ALL. However, secondary life-threatening T-cell immunodeficiency due to shared expression of targeted antigens by healthy and malignant T cells is a main drawback of mAb-or CAR-based immunotherapies for T-ALL and other T-cell malignancies. This review provides a comprehensive update on the different immunotherapeutic strategies that are being currently applied to T-ALL. We highlight recent progress on the identification of new potential targets showing promising preclinical results and discuss current challenges and opportunities for developing novel safe and efficacious immunotherapies for T-ALL.

PROVIDER: S-EPMC7589289 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC7027847 | BioStudies
| S-EPMC8652144 | BioStudies
| S-EPMC5581988 | BioStudies
| S-EPMC5445182 | BioStudies
| S-EPMC9313317 | BioStudies
| S-EPMC3083795 | BioStudies
2009-01-01 | S-EPMC5548385 | BioStudies
| S-EPMC7140076 | BioStudies
| S-EPMC3575759 | BioStudies
| S-EPMC7385186 | BioStudies